Plas-Free Ltd. - Revolutionizing massive bleeding treatment
Currently, there are limited effective solutions to treat excessive bleeding. Plas-Free addresses this unmet medical need by the development of transfusion sets of blood or plasma without the components that create the fibrinolytic cascade. The result is reduction of blood loss in massive bleeding situations.
The size of the market is huge, 36,000 units of red blood cells and 10,000 units of plasma are needed every day in the U.S. Nearly 21 million blood components are transfused each year in the U.S.
Plas-Free is operating under the umbrella of NGT3VC and receives financial support from the Israeli Authority for Innovation.
Massive blood loss can occur upon:
- Trauma (Car Accidents, combats, falls and injuries)
- Surgery (liver transplantation, open heart surgery …)
- Childbirth [Postpartum hemorrhage (PPH)]
- Disseminated intravascular coagulation (DIC)
- Brain hemorrhage
- Stomach ulcers
- Gastro intestinal Bleeding
- Blood vessel rupture can cause a sudden loss of blood
In all of these events there is a need for efficient transfusion kits of blood or plasma for the treatment of an excessive bleeding.
According to the National Trauma Institute (NTI) over 192,000 patients die every year in the US due to blood loss associated with injury. Plas-Free addresses the market of bleeding disorders, which was estimated at approximately $5.30 billion in 2015 and is expected to reach approximately $ 6.70 billion by 2021, growing at a CAGR of around 4.0% between 2015 and 2021.
The proprietary product is an innovative medical device that removes plasminogen form blood and/or plasma. It is a module unit which can be incorporated in conventional Apheresis systems, designed to remove key factors of the fibrinolytic system. By doing so, the result is blood and plasma products with enhanced coagulation properties for improved treatment of excessive bleeding.
Intellectual Property (IP)
The novel technology is covered by strong IP coverage.
Prof. Abed Elrauf Hijazi, M.D – Founder & CSO
Prof. Higazi is the head of the Division of Laboratories & Department of Clinical Biochemistry Hadassah University Hospital, Jerusalem. Prof. Higazi is also the inventor and founder of Thrombotech Ltd. and Pam-Bio Ltd.Prof. Higazi, whose particular expertise is in the area of enzymology, the study of enzymes, received his medical education and training in Barcelona, Spain. Currently, Prof. Higazi's main focus is the manipulation of Hemostasis, which is the process regulating the cessation of bleeding and keeping the blood within a damaged blood vessel. Prof. Higazi experience and innovative research place him as a leading scientist in the field of hemostasis. Prof. Higazi has more than 79 peer review articles and more than ten patents.
Zeev Dvashi, PhD– CEO
Former Chief Technology Officer (CTO) at OphtimedRx, a small start-up company that develops innovative drugs for retinal pathologies. In addition, Dr. Dvashi served as technology expert (Biotechnology & Therapeutics) at SNE-IP. In this position, Dr. Dvashi provided project management services as well as supported negotiation for fundraising, developing business strategies and its implementation. Dr. Dvashi received his Ph.D degree from the Cell Research and Immunology Department, The Life Science Faculty, Tel Aviv University, Israel.
Zohar Gendler – Director
Managing Partner & CEO of NGT3VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment in 53 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK, for $480M), Mazor (NASDAQ: MZOR), ReWalk (NASDAQ: RWLK), Corindus (NASDAQ: CVRS), Regentis, and many others.
Zeev Dvashi (Ph.D), CEO, Plas-free Ltd.
NGT3 (Next Generation Technology) Incubator
Wadi El Haj 13 Nazareth
P.O Box 1252 Nazareth Illit ,
Israel Cellular: +972-52-8494433